Explore tweets tagged as #NYValves2024
Very impressive imaging by @JoaoLCavalcante lecturing on aortic regurgitation & LV impact #NYvalves2024 @crfheart @MadalinaGarbi @RigolinVera @PhilGenereuxMD @FabienPraz @jgranadacrf
1
9
31
Sneak Peek to my today's complex case presentation at #NYValves2024. High-surgical risk pt with bileaflet prolapse & severe MR along with severe regurgitation from idiopathic leaflet perforation. Join me to know how we tackled this with transcatheter therapies. @crfheart @hahn_rt
3
8
31
๐ Thank you for making #NYValves2024 a huge success! ๐ Get ready for even more excitement next yearโmark your calendars for #NYValves2025! ๐๏ธโจ #CardioX #CardioTwitter #CardioEd #CardioResearch @anita_asgar @bapat_savrtavr @BurkhoffMd @djc795
1
7
34
Amazing hands on training session on TEE & ICE for Triclip and Evoque by @hahn_rt & Drs Lebehn & Vahl #NYvalves2024 @crfheart . @triciarawh @jgranadacrf @Drroxmehran @azeemlatib @djc795 @EZancanaroMD @modine_thomas @Sticchi_Alex @mirvatalasnag @hzanellamd
0
14
41
TOPAZ Valve. What a case presented by Jรถrg Hausleiter from Germany at #NYValves2024 Severe Carcinoid disease with non existent TV with torrential TR and near perfect results. Itโs amazing where the field is advancing.
0
7
23
#NYValves2024 @crfheart . @JoaoLCavalcante presents the First in Human #DurAVR results. โWhy another BEV? Unique Flow displacement characteristics & promising early imaging data. ๐น20 point biomimetic improvement in LV mass. LV remodeling & restoration of laminar flow hence Ao
3
16
43
Congratulations @hahn_rt for your flawless imaging of the Evoque valve TTVR case by @SusheelKodaliMD #NYValves2024
0
10
44
๐ Is this the future of #TV regurgitation treatment?. ๐ Meet TriFlO, a unique device featuring 3 anchors positioned at the #TV commissures and polymer leaflets to adapt to irregular shape orifices. #NYValves2024 ๐ ๐ #InnovationWithPurpose @gu_asc1
6
10
38
#NYValves2024 @crfheart . More innovation in the TV space . ๐นDUO Coaptation system evaluated in the TANDEM I trial. ๐นTriFlo first in human results
#NYValves2024 @crfheart . Innovation & FDA . Session on Tricuspid heterotopic technologies . true innovation w zero contrast implants described . ๐นCAVI TricValve: procedure for those not amenable to TV-TEER due to anatomy & comorbidities. STS often high. evidence of RV
1
6
17
Just OUT by @PradeepYadavMD on the 8F Siegel #TAVR with 2X radial ๐ช๐ผRhenium stent. Balloon mounted, shorter balloon, commissural alignment. Fully expansion even in bicuspid. Game changer? #NYValves2024 @TCTMD @crfheart @DLBHATTMD @bapat_savrtavr @KendraGrubb @igeorge1975 @djc795
5
46
152
#NYValves2024 exceeded all expectations! A heartfelt thank you to our attendees, supporters, program directors, and faculty for making this first meeting a remarkable success. ๐โจ See you next year at #NYValves2025! ๐. #CardioX #CardioTwitter #CardioEd
2
15
67
๐ Is this the future of #TMVR? Discover ValSync, an implant that adjusts w/saline-filled balloons to fit each patientโs unique valvular anatomy. Explore the design and data behind this innovation at #NYValves2024 ๐ ๐ . #InnovationWithPurpose @gu_asc1
1
5
46
#NYValves2024 @crfheart . Innovation & FDA . Session on Tricuspid heterotopic technologies . true innovation w zero contrast implants described . ๐นCAVI TricValve: procedure for those not amenable to TV-TEER due to anatomy & comorbidities. STS often high. evidence of RV
1
10
30
๐ Introducing Cusper, a novel transcatheter device for #AR. Designed to fill regurgitant orifice of #AV, it merges an artificial cusp w/native valve to prevent backflow into LV during diastole. #NYValves2024 ๐ ๐@YairFeld #innovationWithPurpose @gu_asc1
5
31
135
๐ #TEER is the gold standard for MR but has limitations. Enter Tioga: a novel #TMVR approach w/unique anchoring mechanism and adaptable valve prosthesis. Explore the #NYValves2024 presentation from @azeemlatib ๐๐ . #InnovationWithPurpose @gu_asc1
3
26
67
๐ก Curious about solutions for severe, symptomatic #TR? Discover the Laplace #TTVR system! Designed for procedural simplicity & adaptability, it tackles diverse pathologies. ๐ #NYValves2024 early data @DrTomWaggoner ๐ ๐ . #InnovationWithPurpose @gu_asc1
0
9
32
๐ก Simple may be best for #TTVR in patients with severe #TR. Trillium is a streamlined solution with a shorter implantation time and no echo guidance or general anesthesia needed. ๐ฅ. #NYValves2024 ๐ ๐.@PhilippLurz . #InnovationWithPurpose @gu_asc1
2
19
45
๐ Introducing the MonarQ System for #TTVR. ๐ฅ Designed for both transfemoral & transjugular delivery, it targets patients w/symptomatic, severe TR at high surgical risk. Early data at #NYValves2024 shows promise. ๐ ๐ . #InnovationWithPurpose @gu_asc1
1
12
49